Skip to main content
Premium Trial:

Request an Annual Quote

Medicyte Licenses Life Technologies' Lentiviral Vector Technology

NEW YORK (GenomeWeb News) – German firm Medicyte today said that it has licensed lentiviral vector technology from Life Technologies for use in developing cell-based assays.

Medicyte said that it would incorporate the licensed technology into its Upcyte cell products for the biopharma and academic research markets. Financial and other terms of the alliance were not disclosed.

"With the technology we have licensed from Life Technologies, we are capable to bring more predictive, reliable, and standardized cell strains on the market," Medicyte CEO Joris Braspenning said in a statement.

Medicyte's Upcyte technology is used to proliferate primary cells, which are used in cell-based assays for research, screening, and drug development.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.